Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tenax Therapeutics (TENX) EBITDA (2016)

Historic EBITDA for Tenax Therapeutics (TENX) over the last 6 years, with Q4 2016 value amounting to $33.6 million.

  • Tenax Therapeutics' EBITDA rose 37751.71% to $33.6 million in Q4 2016 from the same period last year, while for Dec 2016 it was $30.4 million, marking a year-over-year increase of 13699.13%. This contributed to the annual value of -$19.5 million for FY2024, which is 35281.84% down from last year.
  • Per Tenax Therapeutics' latest filing, its EBITDA stood at $33.6 million for Q4 2016, which was up 37751.71% from $4.3 million recorded in Q3 2016.
  • Tenax Therapeutics' EBITDA's 5-year high stood at $68.9 million during Q2 2012, with a 5-year trough of -$74.1 million in Q2 2013.
  • In the last 4 years, Tenax Therapeutics' EBITDA had a median value of -$682843.0 in 2012 and averaged $2.3 million.
  • As far as peak fluctuations go, Tenax Therapeutics' EBITDA surged by 242467.64% in 2012, and later tumbled by 20753.42% in 2013.
  • Quarter analysis of 4 years shows Tenax Therapeutics' EBITDA stood at -$682843.0 in 2012, then tumbled by 10746.09% to -$74.1 million in 2013, then skyrocketed by 83.66% to -$12.1 million in 2015, then surged by 377.52% to $33.6 million in 2016.
  • Its EBITDA was $33.6 million in Q4 2016, compared to $4.3 million in Q3 2016 and $4.6 million in Q2 2016.